I work very closely with top neurosurgeons and neurologists in US and Europe (although not for oncology work), so I am quite keyed in to how Omicron is impacting elective surgeries again. We just had some of our visits over the next couple of weeks postponed at Mt Sinai and couple of places due to Omicron concern. So Q1 will be slow. I forecasted Q1 rev of $3-4M a few weeks back. Either way, I believe we will be over Ex’s $2M forecast for the year in Q1 despite COVID slowing down new patient surgeries.